ATE395349T1 - Polycyclische guanin phosphodiesterase inhibitoren - Google Patents

Polycyclische guanin phosphodiesterase inhibitoren

Info

Publication number: ATE395349T1
Authority: AT; Austria
Prior art keywords: phosphodiesterase inhibitors; polycyclic guanine; guanine phosphodiesterase; polycyclic; inhibitors
Prior art date: 2001-08-28

Application number

AT02761506T

Other languages

English (en)

Inventor

Theodros Asberom

Yueqing Hu

Dmitri Pissarnitski

Ruo Xu

Yuguang Wang

Samuel Chackalamannil

John Clader

Andrew Stamford

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-28

Filing date

2002-08-26

Publication date

2008-05-15

2002-08-26 Application filed by Schering Corp filed Critical Schering Corp

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE395349T1 publication Critical patent/ATE395349T1/de

Links

UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 title 2
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
239000002571 phosphodiesterase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02761506T 2001-08-28 2002-08-26 Polycyclische guanin phosphodiesterase inhibitoren ATE395349T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31539501P	2001-08-28	2001-08-28

Publications (1)

Publication Number	Publication Date
ATE395349T1 true ATE395349T1 (de)	2008-05-15

Family

ID=23224209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02761506T ATE395349T1 (de)	2001-08-28	2002-08-26	Polycyclische guanin phosphodiesterase inhibitoren

Country Status (12)

Country	Link
US (1)	US6969719B2 (de)
EP (1)	EP1421084B1 (de)
JP (2)	JP4450365B2 (de)
CN (2)	CN1315835C (de)
AR (1)	AR036674A1 (de)
AT (1)	ATE395349T1 (de)
CA (1)	CA2457944C (de)
DE (1)	DE60226615D1 (de)
ES (1)	ES2302835T3 (de)
MX (1)	MXPA04001891A (de)
PE (1)	PE20030415A1 (de)
WO (1)	WO2003020724A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020091129A1 (en) *	2000-11-20	2002-07-11	Mitradev Boolell	Treatment of premature ejaculation
JP3945985B2 (ja) *	2000-12-28	2007-07-18	株式会社リコー	デジタルカメラ装置
US7354923B2 (en)	2001-08-10	2008-04-08	Palatin Technologies, Inc.	Piperazine melanocortin-specific compounds
US7456184B2 (en)	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
WO2003013571A1 (en)	2001-08-10	2003-02-20	Palatin Technologies, Inc.	Peptidomimetics of biologically active metallopeptides
JP4450365B2 (ja) *	2001-08-28	2010-04-14	シェーリングコーポレイション	多環式グアニンホスホジエステラーゼｖ阻害剤
EP1575916B1 (de)	2001-08-31	2013-05-22	The Rockefeller University	Phosphodiesteraseaktivität und regulation der durch phosphodiesterase-1-b vermittelten signalvermittlung im hirn
CN1585771A (zh) *	2001-11-09	2005-02-23	先灵公司	多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
CN101538224A (zh) *	2002-05-31	2009-09-23	先灵公司	制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
SI1509525T1 (sl) *	2002-05-31	2006-12-31	Schering Corp	Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
DE10230311A1 (de) *	2002-07-05	2004-01-22	Degussa Ag	Verfahren zur Katalysator-freien Herstellung von O-Alkyl-N-cyanformimidaten
MXPA06005681A (es) *	2003-11-21	2006-08-17	Schering Corp	Formulaciones de inhibidores de la fosfodiesterasa v.
WO2005118166A2 (en)	2004-06-04	2005-12-15	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical composition containing irbesartan
AU2006229840B2 (en) *	2005-03-25	2010-12-23	Merck Sharp & Dohme Corp.	Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2006133261A2 (en)	2005-06-06	2006-12-14	Intra-Cellular Therapies, Inc.	Organic compounds
WO2007000764A2 (en) *	2005-06-27	2007-01-04	Daniel Drai	Compositions and methods for enhancement of sexual function
US20070042957A1 (en) *	2005-08-19	2007-02-22	Mayo Foundation For Medical Education And Research	Type v phosphodiesterase inhibitors and natriuretic polypeptides
EP1919287A4 (de) *	2005-08-23	2010-04-28	Intra Cellular Therapies Inc	Organische verbindungen zur behandlung einer verringerten dopamin-rezeptorsignalisierungs-aktivität
US9012454B2 (en)	2005-12-09	2015-04-21	Mayo Foundation For Medical Education And Research	Sexual dysfunction
JP2007290996A (ja) *	2006-04-24	2007-11-08	Ube Ind Ltd	４−アミノテトラヒドロピランの製法
WO2008063505A1 (en)	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
US8349858B2 (en) *	2007-06-21	2013-01-08	Merck Sharp & Dohme	Polycyclic guanine derivatives and use thereof
ES2588238T3 (es)	2007-12-06	2016-10-31	Intra-Cellular Therapies, Inc.	Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
EP2939676A1 (de) *	2007-12-06	2015-11-04	Intra-Cellular Therapies, Inc.	Organische Verbindungen
MX2011005934A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
EA201170769A1 (ru) *	2008-12-06	2012-02-28	Интра-Селлулар Терапиз, Инк.	Органические соединения
AU2009322899A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
AU2009322903A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
PE20110922A1 (es)	2008-12-06	2012-01-22	Intra Cellular Therapies Inc	DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
CN101747282A (zh)	2008-12-10	2010-06-23	上海特化医药科技有限公司	一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
WO2010098839A1 (en)	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (de)	2009-05-13	2013-08-07	Intra Cellular Therapies Inc	Organische verbindungen
WO2011016861A2 (en)	2009-08-05	2011-02-10	Intra-Cellular Therapies, Inc.	Novel regulatory proteins and inhibitors
US20120316176A1 (en) *	2009-12-22	2012-12-13	Deen Tulshian	DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
US9763948B2 (en)	2010-05-31	2017-09-19	Intra-Cellular Therapies, Inc.	PDE1 inhibitory compounds and methods
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
EP2575817A4 (de)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	Organische verbindungen
EP2717877B1 (de)	2011-06-10	2017-11-08	Intra-Cellular Therapies, Inc.	Organische verbindungen
EP2956141A4 (de)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	Neuartige verwendungen
ES2717688T3 (es)	2013-03-15	2019-06-24	Intra Cellular Therapies Inc	Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
DK2970279T3 (da)	2013-03-15	2020-11-30	Intra Cellular Therapies Inc	Organiske forbindelser
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
DK3157926T3 (da)	2014-06-20	2019-08-19	Intra Cellular Therapies Inc	Organiske forbindelser
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
CA2961212C (en)	2014-09-17	2024-02-06	Intra-Cellular Therapies, Inc.	Compounds and methods
WO2016090382A1 (en)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Organic compounds
BR112017012007B1 (pt)	2014-12-06	2022-11-01	Intra-Cellular Therapies, Inc	Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
US11291666B2 (en)	2016-09-12	2022-04-05	Intra-Cellular Therapies, Inc.	Uses
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
US12410175B2 (en)	2019-09-03	2025-09-09	Intra-Cellular Therapies, Inc.	Compounds
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease
CN119039287A (zh) *	2023-05-29	2024-11-29	中国药科大学	一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1938016A1 (de)	1969-07-23	1971-01-28	Fischer Ohg Arzneimittelwerk	Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten
FR2116302A1 (en)	1970-12-07	1972-07-13	Brun Lab Sa Le	8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
ES2033922T3 (es)	1986-08-28	1993-04-01	Sandoz Ag	Procedimiento para preparar nuevos derivados de xantina.
US5321029A (en) *	1988-11-14	1994-06-14	Beecham-Wuelfing Gmbh & Co.K.G.	Xanthines
GB8906792D0 (en)	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
FR2654935B1 (fr)	1989-11-28	1994-07-01	Lvmh Rech	Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
NZ238609A (en) *	1990-06-21	1993-12-23	Schering Corp	Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
GB9020921D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
GB9020959D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
ES2148170T3 (es) *	1990-12-21	2000-10-16	Beecham Group Plc	Derivados de xantina.
GB9210839D0 (en)	1992-05-21	1992-07-08	Smithkline Beecham Plc	Novel compounds
GB9226532D0 (en) *	1992-12-21	1993-02-17	Smithkline Beecham Plc	Compounds
EP0686157A1 (de) *	1993-02-26	1995-12-13	Schering Corporation	2-benzylpolycyclisch guaninderivate und verfahren zu ihrer herstellung
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
GB9423911D0 (en) *	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
GB9514464D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5824683A (en) *	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9612514D0 (en) *	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
US6403597B1 (en) *	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
HU227841B1 (en)	1997-11-12	2012-05-02	Bayer Pharma AG	2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
DE19816857A1 (de)	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1999062905A1 (en)	1998-06-03	1999-12-09	Almirall Prodesfarma, S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087362A (en) *	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition
US6023640A (en) *	1999-03-29	2000-02-08	Ross; Jesse	Method contributing to obviating male impotency
US20020091129A1 (en) *	2000-11-20	2002-07-11	Mitradev Boolell	Treatment of premature ejaculation
JP4450365B2 (ja) *	2001-08-28	2010-04-14	シェーリングコーポレイション	多環式グアニンホスホジエステラーゼｖ阻害剤

2002
- 2002-08-26 JP JP2003524994A patent/JP4450365B2/ja not_active Expired - Fee Related
- 2002-08-26 US US10/227,778 patent/US6969719B2/en not_active Expired - Fee Related
- 2002-08-26 CN CNB028167066A patent/CN1315835C/zh not_active Expired - Fee Related
- 2002-08-26 EP EP02761506A patent/EP1421084B1/de not_active Expired - Lifetime
- 2002-08-26 MX MXPA04001891A patent/MXPA04001891A/es active IP Right Grant
- 2002-08-26 AT AT02761506T patent/ATE395349T1/de not_active IP Right Cessation
- 2002-08-26 DE DE60226615T patent/DE60226615D1/de not_active Expired - Lifetime
- 2002-08-26 ES ES02761506T patent/ES2302835T3/es not_active Expired - Lifetime
- 2002-08-26 CA CA002457944A patent/CA2457944C/en not_active Expired - Fee Related
- 2002-08-26 AR ARP020103195A patent/AR036674A1/es unknown
- 2002-08-26 CN CNA2005101248185A patent/CN1781920A/zh active Pending
- 2002-08-26 WO PCT/US2002/027181 patent/WO2003020724A1/en not_active Ceased
- 2002-08-27 PE PE2002000821A patent/PE20030415A1/es not_active Application Discontinuation
2005
- 2005-08-08 JP JP2005230176A patent/JP2005325138A/ja active Pending

Also Published As

Publication number	Publication date
JP4450365B2 (ja)	2010-04-14
WO2003020724A1 (en)	2003-03-13
CN1547583A (zh)	2004-11-17
JP2005502684A (ja)	2005-01-27
JP2005325138A (ja)	2005-11-24
AR036674A1 (es)	2004-09-29
CN1315835C (zh)	2007-05-16
EP1421084B1 (de)	2008-05-14
MXPA04001891A (es)	2004-06-15
CA2457944C (en)	2009-09-29
ES2302835T3 (es)	2008-08-01
DE60226615D1 (de)	2008-06-26
CN1781920A (zh)	2006-06-07
PE20030415A1 (es)	2003-05-22
HK1064668A1 (en)	2005-02-04
CA2457944A1 (en)	2003-03-13
EP1421084A1 (de)	2004-05-26
US6969719B2 (en)	2005-11-29
US20030153587A1 (en)	2003-08-14

Legal Events

Date	Code	Title	Description
2008-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK1319003T3 (da)	2009-09-28	Xanthin-phosphodiesterase V-inhibitorer
ATE256127T1 (de)	2003-12-15	Betacarbolinderivate als phosphodiesterase- inhibitoren
PT1370553E (pt)	2006-09-29	Inibidores de rhoquinase
ATE278690T1 (de)	2004-10-15	Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
HUS1500055I1 (hu)	2016-03-29	HIV-gátló pirimidinszármazékok
MA25996A1 (fr)	2003-12-31	Inhibiteurs de phosphodiesterase 4.
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
DE60234125D1 (de)	2009-12-03	E inhibitoren
NO20041293D0 (no)	2004-03-26	Alkyn-aryl-fosfodiesterase-4-inhibitorer
DE60218138D1 (de)	2007-03-29	Rho-kinase inhibitoren
CY2015028I2 (el)	2016-07-27	Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
ATE411316T1 (de)	2008-10-15	Pyrrolopyrimidine als phosphodiesterase-vii- hemmer
ATE286049T1 (de)	2005-01-15	Pyridazinonaldose reductase inhibitoren
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
EP1423223A4 (de)	2007-06-13	Schlagverriegelungsspannfutter
IS7287A (is)	2004-05-26	Pýrimídín efnasambönd
IS6868A (is)	2003-07-08	Ný pýrimidínefnasambönd
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe
EP1570847A4 (de)	2008-10-08	Phosphodiesterase 10a-hemmer
NO20041938L (no)	2004-05-11	Anvendelse av fosfodiesterase IV-inhibitorer
DE50201649D1 (de)	2005-01-05	Kondensator
DE50212755D1 (de)	2008-10-23	Bohrfutter
AU2002326765A1 (en)	2003-03-18	Polycyclic guanine phosphodiesterase v inhibitors
HK1066224A (en)	2005-03-18	Polycyclic guanine derivative phosphodiesterase v inhibitors